🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

33 results for “CASI” Clear

  1. Apremilast, Apremilast, Apremilast

    Amgen Technology (Ireland) UC

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  2. BENDAFOLIN 10 mg/ml Injektionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, Napabucasin

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.

    phase 3 small molecule active

    1 trial

  3. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  4. Casimersen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule terminated

    1 trial

  5. Napabucasin, Bendatax 6 mg/ ml, Bendacitabin 38 mg/ml Pulver zur Herstellung einer Infusionslösung

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.

    phase 3 small molecule active

    1 trial

  6. casirivimab+imdevimab

    Regeneron UK Limited

    Immunocompromised

    phase 3 small molecule terminated

    1 trial

  7. casirivimab+imdevimab combination therapy

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule terminated

    1 trial

  8. 2-methoxyestradiol

    CASI Pharmaceuticals

    Relapsed Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  9. CID-103

    CASI Pharmaceuticals

    Chronic Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  10. ENMD-2076

    CASI Pharmaceuticals

    Advanced Adult Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  11. ENMD-2076

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  12. ENMD-2076

    CASI Pharmaceuticals

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  13. MKC-1

    CASI Pharmaceuticals

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  14. MKC-1

    CASI Pharmaceuticals

    Advanced Cancer

    phase 2 small molecule completed

    2 trials

  15. MKC-1

    CASI Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  16. MKC-1

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  17. Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

    CASI Pharmaceuticals

    Carcinoid Tumor

    phase 2 small molecule completed

    1 trial

  18. Panzem NCD

    CASI Pharmaceuticals

    Recurrent Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  19. Panzem Nanocrystal Colloidal Dispersion

    CASI Pharmaceuticals

    Recurrent Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  20. Panzem Nanocrystal Colloidal Dispersion (NCD)

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  21. Panzem® NCD

    CASI Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  22. Panzem® NCD

    CASI Pharmaceuticals

    Metastatic Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  23. casirivimab+imdevimab

    Regeneron UK Limited

    COVID-19

    phase 2 small molecule terminated

    2 trials

  24. casirivimab+imdevimab

    Regeneron UK Limited

    Healthy

    phase 2 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources